Immunoblotting for TGF-beta, alpha-actinin, MMP-13, and mTOR. by Dwight D. Harris (14484648)

“…There was a significant decrease in the ratio of pmTOR to mTOR. …”

Immunoblotting for JAK, STAT, and SMAD. by Dwight D. Harris (14484648)

“…There was also a significant decrease in SMAD and pSMAD in the SIT group. …”

Fibrosis markers. by Dwight D. Harris (14484648)

Immunoblotting for insulin sensitivity markers. by Dwight D. Harris (14484648)

“…There was also a significant decrease in pPKC alpha in the SIT-I myocardium compared to SIT-N. …”

Immunoblotting FOXO1 and insulin receptors. by Dwight D. Harris (14484648)

Decreased Na_v1.5 expression in <i>Scn5a</i>^+/− mice. by Anne-Laure Leoni (366926)

The 5-point summary of CPM dataset. by Gaurav Sandeep Dave (21519884)

Activation of mGluR5 site-specifically decreases spine density in the nucleus accumbens. by Kellie S. Gross (3115299)

RGS5 deletion resulted in decreased peripheral insulin sensitivity and suppressed the Akt/GSK3β signaling pathway in mice fed an HF for 24 weeks. by Wei Deng (17330)

How the variation in inhibitor concentration throughout one day affects the value of IC₅₀/(IC₅₀ + [R]) for different Abl1 inhibitors. by J. Roadnight Sheehan (20141887)

Aggrecan knockdown ATDC5 chondroprogenitor cells have decreased Alcian blue staining and absorbance levels compared to control cells after ITS stimulation. by Juanita K. Hodax (6848540)

Effects of Cyr61 and Wnt5a on regenerating vasculature and musculature. by Devon C. Snow-Lisy (798898)

“…Cyr61KD demonstrated a significant decrease in muscle percentage from 4 to 10 weeks (p<0.05), with levels significantly lower than Cyr61OX at both time points. …”

Effects of conivaptan on brain water content (BWC), blood-brain-barrier (BBB) disruption, plasma and urine sodium and osmolality. by Emil Zeynalov (596088)

“…Following MCAO, Evans Blue (EB) extravasation index (I/C) was increased in vehicle treated mice, and reduced in conivaptan treated mice, naïve, n = 5, vehicle, n = 8, Conivaptan 0.2 mg, n = 8. (C, D) Conivaptan treatment of 0.2 mg resulted in an elevation of plasma sodium and osmolality, and decreased urine sodium and osmolality due to aquaresis. …”

Effects of tolvaptan on brain water content (BWC), plasma and urine sodium and osmolality. by Emil Zeynalov (596088)

Maintenance of a single Zeb2 wt allele rescues PB cytopenia and severe differentiation defects in Zeb1/2 DKO HSPCs. by Jueqiong Wang (11467505)

Decreased survival of MCF7 cells after irradiation with an ultrasonic frequency of 24.5 kHz as determined by XCelligence (Roche). by Annette Geltmeier (779536)

NOX4 depletion decreases cAMP concentration and AQP2 expression in a phosphodiesterase-dependent manner in mpkCCD_cl4 cells. by Eric Féraille (513934)

Cofactors required for Vpu activities. by Charlotte A. Stoneham (10819125)

Final genome size as a function of population size. by Thomas LaBar (739568)

Time concordance metrics for all TFs, pathways as well as genes using both a minimal |logFC| of 0.5 and 1. by Anika Liu (8411805)